...2016 and $18.8 million in a placing in 2017; (E) Nightstar Therapeutics plc (NASDAQ:NITE), formerly NightstaRx Ltd....

...antagonist RPE65 - Retinal pigment epithelium-specific protein 65kDa Karen Tkach Tuzman, Associate Editor Freeline Therapeutics Ltd. Gyroscope Therapeutics Ltd. NightstaRx Ltd. Orbit...

...2016 and $18.8 million in a placing last year; (E) Nightstar Therapeutics plc (NASDAQ:NITE), formerly NightstaRx Ltd....

...Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to...

...Ophthalmic gene therapy company Nightstar Therapeutics Ltd. (London, U.K.) (formerly NightstaRx Ltd.) filed to raise up to...
...is also in Phase III testing as first-line treatment of pancreatic cancer. Elizabeth S. Eaton AAV-XLRPGR AAV2-REP1 Acelarin DCC-2618 Nightstar Therapeutics Ltd. NightstaRx Ltd. NuCana...

...CFO, effective May 1. She was CFO at Stadium Group plc (LSE:SDM). Gene therapy company NightstaRx Ltd....

...Phase I/II trial to evaluate single subretinal injections of AAV-XLRPGR in about 24 male patients. NightstaRx Ltd....
...RPGR) gene Indication Treat X-linked retinitis pigmentosa Endpoint: Safety Status: Phase I/II started Milestone: NA Julian Zhu AAV-XLRPGR NightstaRx Ltd. Retinitis...

...Gene therapy company NightstaRx Ltd. (London, U.K.) named Gregory Robinson CSO. He was CSO at Agilis Biotherapeutics...

...hematology; pulmonary Abingworth Management; Celgene Corp. (NASDAQ:CELG); New Enterprise Associates (NEA); SR One; Versant Ventures NightstaRx Ltd....

...has disclosed investments in seven European companies: Adaptimmune Therapeutics plc , CRISPR Therapeutics AG , NightstaRx Ltd....
...In NightstaRx case, a U.S. investor pushed the company to think bigger. According to Mott, NightstaRx...
...with this platform?" NEA led a $35 million series B round in November. In parallel, NightstaRx...